...Machielse as EVP, CMC and Frank Czworka as SVP, global sales. Machielse was CEO of Vtesse Inc....

...EU. Sucampo gained the 2-hydroxypropyl-b-cyclodextrin targeting cholesterol and sphingolipid storage through its April acquisition of Vtesse Inc....

...EU. Sucampo gained the 2-hydroxypropyl-b-cyclodextrin targeting cholesterol and sphingolipid storage through its April acquisition of Vtesse Inc....

...DMD). In 2013, Cydan raised a total of $26 million. The accelerator launched two companies: Vtesse Inc....
...Cambridge, Mass.) (see BioCentury, April 15, 2013 ). In April, Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) acquired Vtesse...
...A/S (NASDAQ:ASND). Cydan Development Inc. , Cambridge, Mass. Chris Lieu IMR-687 VTS-270 Ascendis Pharma A/S Bristol-Myers Squibb Co. Cydan Development Inc. Imara Inc. Vtesse Inc. Phosphodiesterase-9...

...for Cydan. The Vtesse experience has shown that that’s possible,” said Agarwala. Cydan’s first spinout, Vtesse Inc....
...up front by Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) in April, about two years after its launch. Vtesse...
...additional spinouts, and expects to announce its third newco next year. Virginia Li, Staff Writer Cydan Development Inc. Vtesse Inc. Longitude...

...DMD). In 2013, Cydan raised a total of $26 million. The accelerator launched two companies: Vtesse Inc....
...Cambridge, Mass.) (see BioCentury, April 15, 2013) . In April, Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) acquired Vtesse...
...Svenstrup was director of CMC at Ascendis Pharma A/S (NASDAQ:ASND). Chris Lieu IMR-687 VTS-270 Bristol-Myers Squibb Co. Cydan Development Inc. Imara Inc. Vtesse Inc. Phosphodiesterase-9...

...each company while giving Vtesse investors an exit and a share of any upside. The Vtesse...
...cost more than expected, while VTS-270 helps fill a hole in Sucampo’s pipeline. Sucampo acquired Vtesse...
...disease Priority Review voucher, Vtesse shareholders would receive an undisclosed portion of the net proceeds. Vtesse...

...Sucampo acquired rare disease company Vtesse for $200 million. Vtesse shareholders are to receive $170 million...
...and 2.8 million Sucampo shares up front, plus mid-single to double-digit royalties. Sucampo will gain Vtesse's...
...Mass.). Vtesse Inc. , Gaithersburg, Md. Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP), Rockville, Md. Business: Endocrine/Metabolic Chris Lieu VTS-270 Sucampo Pharmaceuticals Inc. Vtesse Inc....

...Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) acquired rare disease company Vtesse Inc. (Gaithersburg, Md.) for $200 million. Vtesse shareholders...
...million in cash and 2.8 million Sucampo shares up front, plus royalties. Sucampo will gain Vtesse's...
...Vtesse has set aside $1.7 million for the foundation, and Sucampo will match the contribution. Vtesse...

...about 51 patients, including those from the first part. The trial includes an open-label extension. Vtesse Inc....
...Status: Completed Phase IIb/III enrollment Milestone: Phase IIb/III data (early 2018); submit regulatory application (2018) Julian Zhu 2-hydroxypropyl-b-cyclodextrin HPBCD VTS-270 Vtesse Inc....